OTCM
ENSCW
Market cap4mUSD
Jun 10, Last price
0.02USD
1D
-3.77%
1Q
30.68%
IPO
-95.82%
Name
Ensysce Biosciences Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
77.81%
Rev. gr., 5y
%
Revenues
0k
-100.00%
Net income
-7.99t
L+75,258,255.87%
CFO
-7.50t
L+69,598,346.45%
Earnings
Aug 12, 2025
Profile
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP prodrug candidate of oxycodone, which is in Phase II clinical trial for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat that is in Phase I clinical trial for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF329, an extended-release prodrug of hydromorphone that is similar to PF614; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse; and PF26810, an extended-release prodrug of methadone for opioid use disorder. The company is based in La Jolla, California.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | |
| Income | ||||||||
Revenues | 2,231 -11.61% | 2,523 -28.54% | ||||||
Cost of revenue | 11,940,165,000 | 20,536 | 46,581 | |||||
Unusual Expense (Income) | ||||||||
NOPBT | (11,940,165,000) | (18,306) | (44,058) | |||||
NOPBT Margin | ||||||||
Operating Taxes | 754 | |||||||
Tax Rate | ||||||||
NOPAT | (11,940,165,000) | (18,306) | (44,812) | |||||
Net income | (7,987,225,000) 75,258,255.87% | (10,613) -57.48% | (24,962) -14.36% | |||||
Dividends | (290,000) | (913) | ||||||
Dividend yield | 2,039.78% | 56.39% | ||||||
Proceeds from repurchase of equity | 1,670 | 9,050 | 3,783 | |||||
BB yield | -11.75% | -377.10% | -233.62% | |||||
| Debt | ||||||||
Debt current | 301,660,000 | 855 | 4,267 | |||||
Long-term debt | 167 | |||||||
Deferred revenue | ||||||||
Other long-term liabilities | 10 | 26 | 310 | |||||
Net debt | (3,200,417,000) | (269) | 1,286 | |||||
| Cash flow | ||||||||
Cash from operating activities | (7,502,700,000) | (10,780) | (17,887) | |||||
CAPEX | 2 | |||||||
Cash from investing activities | 4 | |||||||
Cash from financing activities | 9,881,173,000 | 8,756 | 8,766 | |||||
FCF | (11,940,165,189) | (18,089) | 24,676,161 | |||||
| Balance | ||||||||
Cash | 3,502,077,000 | 1,124 | 3,148 | |||||
Long term investments | ||||||||
Excess cash | 3,502,077,000 | 1,012 | 3,022 | |||||
Stockholders' equity | (129,872,782,000) | (121,885) | (111,246) | |||||
Invested Capital | 127,967,250,597 | 122,115 | 111,933 | |||||
ROIC | ||||||||
ROCE | 626.61% | |||||||
| EV | ||||||||
Common stock shares outstanding | 1,747 | 2,264 | 180 | |||||
Price | 8.14 667.92% | 1.06 -88.22% | 9.00 -99.20% | |||||
Market cap | 14,217 492.41% | 2,400 48.20% | 1,619 -98.29% | |||||
EV | (3,528,885,783) | 1,803 | 2,591 | |||||
EBITDA | (10,742,965,000) | (17,980) | (44,058) | |||||
EV/EBITDA | 0.33 | |||||||
Interest | 1,290,444,000 | 354 | 110 | |||||
Interest/NOPBT | ||||||||